高硬度富锶地下水的软化沉淀-超滤膜联用工艺

针对一种高硬度富锶地下水,分别采用石灰和石灰-碳酸钠两种方法,利用药剂软化/超滤膜工艺对其进行软化处理,同时考察了药剂投量对出水锶含量的影响。结果表明,采用石灰软化/超滤膜法,Ca(OH)2最佳投加量为270 mg/L时,出水总硬度(以CaCO3计)由287.12 mg/L降低到96.44 mg/L,硬度去除率为66.41%,出水锶含量也由原水中的0.37 mg/L下降为0.21 mg/L;而采用石灰-碳酸钠软化/超滤膜法,Ca(OH)2和Na2CO3最佳投加量分别为270 mg/L、160mg/L时,出水总硬度降低到60.34 mg/L,硬度去除率达78.98%,锶含量仅为0.02 mg/L。2种处理方法出水总硬度均达到预期目标,石灰软化/超滤膜法可使出水锶含量满足富锶水的要求,而石灰-碳酸钠软化/超滤膜法则造成了对人体有益微量元素锶的大量损失。     

抗生素抗性基因在两级废水处理系统中的分布和去除

废水处理系统被认为是水环境中抗生素抗性基因(ARGs)的重要污染源.为探究ARGs在废水处理系统中的分布特征和去除情况,选取某精细化工园区内的制药废水处理系统和园区综合性废水处理系统,使用PCR和实时荧光定量PCR对不同处理单元中ARGs的存在情况和丰度变化进行研究.在两个系统进水中分别检出了10种和15种ARGs,其中以四环素类和磺胺类ARGs居多,并首次检出了dfrA13基因.进水中sulⅠ和sulⅡ基因的丰度最高,随后依次是dfrA13、tetQ、floR、tetO和tetW基因.制药废水处理系统使总ARGs浓度上升了0.21个数量级,出水汇入园区综合性废水处理系统再次处理,其对综合性废水处理系统进水中总ARGs的贡献率为5.05%.综合性废水处理系统使总ARGs浓度下降了1.03个数量级,残留ARGs同最终出水一起直接排海,对近海环境中微生物群落的潜在影响有待深入研究.     

高强度好氧生物反应器处理制药废水的启动和稳定性试验研究

高强度好氧反应器(jet-loop compact reactor,JLCR)采用射流曝气强制溶氧.对JLCR处理制药废水进行了试验研究,考察了JLCR的运行效果、反应器的启动与污泥驯化、抗冲击负荷性能以及污泥沉降性能等.初步结果表明,该系统启动时间较短,运行稳定,COD去除效果较好.进水COD为8000 mg/L左右时,去除率达到80%.     

含酚制药废水处理技术

针对含酚制药污水COD含量高、难降解等特点，综述了采用物化、生化法于一体的方法处理废水，并且从机理上阐述了该方法解决上述问题的可行性及实际应用。     

小型制药厂污水处理工程设计

小型制药厂生产废水具有水质、水量波动大的特点,应用普通处理工艺很难适应水质、水量的大幅度波动。多级水解酸化-接触氧化工艺具有较高的抗冲击负荷,工程实例结果表明应用该工艺可以使处理设施长期稳定运行,并实现出水达标排放。     

BIOFOR工艺处理中成药废水

采用一段式生物过滤氧化反应器(BIOFOR)处理中成药生产废水与部分生活污水的综合废水。运行1a的结果表明:当进水CODCr为500mg/L,BOD5为230mg/L,SS为250mg/L,BOD5容积负荷为4·1kg/(m3·d),气水比为6·6∶1时,除冬季排水CODCr偶尔高于60mg/L外,其它季节排水中CODCr≤50mg/L,系统出水达到《污水综合排放标准》(GB8978-1996)一级排放标准。     

催化光度法测定中成药中痕量铬

研究了Cr（Ⅵ）催化H2O2氧化溴甲酚红（BR）的反应。在HAc-NaAc介质中，以溴化十六烷基吡啶（CPB）为增敏剂，测定波长为588nm，Cr(Ⅵ）浓度在0－0.06mg/L内与吸光度呈线性关系。该法用于中成药乌鸡白凤丸中铬含量的测定，结果令人满意。     

普光高含硫气田水中H2S去除技术研究

文章探讨了通常用于水中H2S去除的方法,对比方法的优缺点,提出以NaClO为主要脱硫剂的处理方法。通过对采出水的脱硫氧化剂优选试验、NaClO连续脱硫试验,并将试验研究结果应用于普光高含硫气田水脱硫处理。试验证明:采用NaClO可以安全、高效地去除采出水中的H2S,处理后的气田水中硫化物的含量小于1mg/L。     

中药制药企业事故隐患及防范措施

分析了制药企业目前存在的几个主要事故隐患,有针对性地提出了预防事故发生的措施。     

The presence of pharmaceuticals in the environment due to human use – present knowledge and future challenges

Intensive research on pharmaceuticals in the environment started about 15 years ago. Since then a vast amount of literature has been published. The input and presence of active pharmaceutical ingredients (APIs) and their fate in the environment were and is still of high interest. As it has been extensively demonstrated that the active compounds are present in the environment some of the research interest has moved from analysis of the compounds, which is still undertaken, to effect studies in the lab and in field trials. It has been found that environmental concentrations can cause effects in wildlife if proper tools are applied for effect assessment. The question of mixture toxicity has gained more and more attention. It has been learned that classical tests may underestimate effects and risks. Work has been done in the field of risk assessment and risk management. As for risk management strategies to eliminate pharmaceuticals from wastewater or from the effluent of sewage treatment plants have been proposed and investigated. A tremendous amount of literature can now be found describing technical management measures such as oxidative or photolytic effluent treatment, filtering techniques, and application of charcoal. It has been learned however, that each of these approaches has its specific shortcomings. Therefore, additional approaches such as including people handling and using the compounds, and focusing on the properties of the compounds (“green pharmacy”) came into focus. Accordingly, this review gives an overview of the present state of knowledge presenting typical results and lines of discussion. This review makes no claim to give a complete overview including the full detailed body of knowledge of pharmaceuticals in the environment. Rather, it addresses important and typical topics to stimulate discussion.